Abstract
Pharmaceutical Patent AnalystVol. 4, No. 3 Hot TopicGeneric product entry in EU marketsLorna BrazellLorna BrazellE-mail Address: lorna.brazell@osborneclarke.com Partner, Osborne Clarke, One London Wall London EC2Y 5EBSearch for more papers by this authorPublished Online:1 Jun 2015https://doi.org/10.4155/ppa.15.6AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1 Kollagenase I and II GRUR 461 + 462. (2014).Google Scholar2 Novartis AG v. Alvogen IPCO SARL and Focus Farma B.V., District Court The Hague, 23 December 2013, Case No. C/09/452370/KG ZA 13–1160.Google Scholar3 [2010] EWCA Civ 1110.Google Scholar4 Fifth report on Patent Settlement Agreement. http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/patent_settlements_report5_en.pdf.Google Scholar5 Cour d'appel de Paris, 23 September 2014, Docket No 12/21810.Google ScholarFiguresReferencesRelatedDetails Vol. 4, No. 3 Follow us on social media for the latest updates Metrics Downloaded 42 times History Published online 1 June 2015 Published in print May 2015 Information© Future Science LtdFinancial & competing interests disclosureThe author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
